"Our company’s focus and expertise is comprehensive renal therapy management. As rates of diabetes, obesity and heart disease climb and threaten to dramatically increase the incident rates for renal disease, we want to assist payers, doctors and patients by providing the highest quality and most cost-effective care now," said Peter Sauer, president at Fresenius Health Partners.“We value our business relationship with Fresenius Medical Care and the complementary capabilities they can provide to improve the care our members receive. We believe the new program is one more way we can increase value and quality within the health care system,” said Bill Stout, head of Aetna’s National Provider Contracting. Aetna commercial and Medicare medical members in targeted Northeast markets currently have access to the new program. Additional expansion is expected throughout 2012. About Aetna Aetna is one of the nation's leading diversified health care benefits companies, serving approximately 36.4 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, and medical management capabilities and health care management services for Medicaid plans. Our customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. For more information, see www.aetna.com. About Fresenius Medical Care Fresenius Medical Care (NYSE: FMS) is the world’s leading company devoted to patient-oriented renal therapy. Through more than 2,900 clinics in North America, Europe, Latin America, Asia-Pacific and Africa, we provide kidney dialysis treatments to approximately 228,000 patients worldwide. We are also the world's leading maker of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Chronic kidney failure is a condition that affects about 2 million individuals worldwide. For more information about the company’s more than 1,800 U.S. dialysis facilities, visit www.ultracare-dialysis.com (in English and Spanish). For more information about Fresenius Medical Care, visit www.fmc-ag.com or www.fmcna.com. Legal Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.